Efficacy and Safety of Intensive Maintenance Chemotherapy Regimen for Treatment of Children and Adolescents with Lymphoblastic Lymphoma for Stage III-IV

Abstract

To investigate the efficacy and safety of intensive maintenance chemotherapy regimen for treatment of children and adolescents with lymphoblastic lymphoma at stage Ⅲ-Ⅳ. The clinical data of 87 children and adolescents with lymphoblastic lymphoma at stage Ⅲ-Ⅳ were analyzed retrospectively from July 2009 to July 2015. All patients received the treatment of modified NHL-BFM-90/95 regimen, and divided into 2 groups: the control group (62 patients) with conventional maintenance chemotherapy regimen, and the intensive regimen group (25 patients) with intensive maintenance chemotherapy regimen. The event-free survival (EFS) rate and overall survival (OS) rate during follow-up for 5 years, recurrence rate, mortality, and toxic and side effects were compared between 2 groups. There was no significant difference in the EFS rate and OS rate after follow-up for 5 years between 2 groups (P＞0.05). There was no significant difference in the EFS rate and OS rate after follow-up for 5 years between clinical stage for Ⅲ and Ⅳ, immunotyping for T-LBL and B-LBL and morderate risk and high risk in 2 groups (P＜0.05). There was no significant difference in the recurrence rate and mortality after followed-up between 2 groups (P＞0.05). The incidence of myelosuppression for Ⅲ-Ⅳ grade during maintenance therapy in intensive regimen group were significantly higher than that in control group (P＜0.05). Compared with conventional maintenance chemotherapy regimen, intensive maintenance chemotherapy regimen in the treatment of children and adolescents with lymphoblastic lymphoma for stage Ⅲ-Ⅳ possess the same survival benefit, but may cause increased severe bone marrow suppression risk.